Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 7Phase 1/2 5Phase 3 4Phase NA 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Breast Neoplasms 12Ovarian Neoplasms 11Fallopian Tube Neoplasms 10Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 5Brenner Tumor 5Lung Neoplasms 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Carcinoma 3Adenocarcinoma of Lung 3Oropharyngeal Neoplasms 2Neurotoxicity Syndromes 2Mouth Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinosarcoma 2Carcinoma, Transitional Cell 2Vomiting 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrent Uterine Corpus Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Cancer Resectable 1Pancreatic Adenocarcinoma 1Pancreas Adenocarcinoma 1Pain 1Ovarian Germ Cell Cancer 1

Interventions

Carboplatin 67Cisplatin 57Paclitaxel 42Radiotherapy 35Pemetrexed 34Gemcitabine 31Docetaxel 31Etoposide 25pembrolizumab 21Vinorelbine 20Erlotinib Hydrochloride 13Magnetic Resonance Spectroscopy 12Gefitinib 11Specimen Handling 10Radiosurgery 10Drug Therapy 10Bevacizumab 10durvalumab 9Nivolumab 9Vinblastine 6Topotecan 6Surgical Procedures, Operative 6Cyclophosphamide 6atezolizumab 5Standard of Care 5Platinum 5Immunoglobulin G 5Ifosfamide 5Disulfides 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Lung Neoplasms × Taxes × Clear all
NCT04267848 2026-06-03

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

National Cancer Institute (NCI)

Phase 3 Recruiting
1,210 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06096844 2026-06-03

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

National Cancer Institute (NCI)

Phase 3 Recruiting
304 enrolled
Thoracic

Lung Neoplasms

NCT04092283 2026-05-29

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
660 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05624996 2026-05-04

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

NRG Oncology

Phase 3 Recruiting
474 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡